More importantly, in patients who did not respond to fluid by an increase in cardiac output (non-responders), this led to a significant decrease in oxygen delivery [3].
In responders this effect was obtained in 3 5 days [309, 310].
Open phase improvement was unlikely due to prophylactic treatment changes because in four out of six responders, this treatment was stopped, dose-decreased or unchanged.
"For many responders, this is a matter of life and death and I urge you to do everything possible to speed up this process".
It was also shown with immunohistochemistry that although there is epithelial layer restoration after treatment with infliximab in responders, this restoration is incomplete and epithelial cell mass is still decreased in comparison with normals.
When excluding indeterminate responders, this trend increased in strength and significance for the IP-10 test (p = 0.005), but there was still no trend observed for QFT-IT (p = 0.17).
For non-responders, this oxytocin pattern was almost identical for SRI-treated and placebo-treated cases.
With the larger proportion of patients with a previous stroke among non-responders, this could have affected the results on illness perceptions.
In responders, this correlation was highest in the double-negative subset (R2 = 0.71; P ≤ 0.0001) but was lowest in non-responders and controls (R2 = 0.520; P ≤ 0.0437 and R2 = 0.384; P ≤ 0.0080, respectively).
By focusing on differences in dynamic changes on RNA and/or protein expression profiles between responders and non-responders, this approach should detect markers of resistance to Herceptin and/or mechanisms causally associated with the resistant phenotype.
Thus, although CBT may be an efficacious augmentation treatment in SRI partial responders, this has not been established in a randomized controlled trial in this patient population against an appropriate control condition.
